Table of contents

Expand All Topics

Ovarian cancer

What's new

The American Society of Clinical Oncology (ASCO) has released updated guidelines on neoadjuvant chemotherapy (NACT) for newly diagnosed advanced ovarian cancer. NACT with a platinum-taxane doublet is recommended for patients eligible for primary cytoreductive surgery but unlikely to achieve complete cytoreduction or having high perioperative risk. Interval cytoreductive surgery (ICS) after ≤4 cycles of NACT, followed by post-ICS chemotherapy to complete 6 cycles, is recommended, with hyperthermic intraperitoneal chemotherapy (HIPEC) suggested during ICS. Options for maintenance therapy include bevacizumab, PARP inhibitors, and clinical observation. .

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of ovarian cancer are prepared by our editorial team based on guidelines from the American Society of Clinical Oncology (ASCO 2025,2022,2021,2020), the American Academy of Family Physicians (AAFP 2023), the European Society of Medical Oncology (ESMO 2023,2018,2016), the Society of Obstetricians and Gynaecologists of Canada (SOGC 2020,2018), the U.S. Preventive Services ...
Show more

Screening and diagnosis

Indications for screening, general population: as per AAFP 2023 guidelines, do not obtain screening for OC in non-high-risk asymptomatic females.
D
Create free account

More topics in this section

  • Indications for screening (patients at risk)

  • Monitoring of ovarian cysts (general population)

  • Monitoring of ovarian cysts (pregnant patients)

  • Differential diagnosis

Classification and risk stratification

Risk assessment
As per ACOG 2017 guidelines:
Elicit a detailed personal and family history for breast, gynecologic, and colon cancer to help categorize patients based on their risk (average risk or high risk) of developing epithelial OC.
E
Maintain an appropriate level of suspicion when potentially relevant signs and symptoms of OC are present.
E
Create free account

More topics in this section

  • Staging

  • Prognosis

Diagnostic investigations

History and physical examination: as per ASCO 2021 guidelines, obtain a clinical assessment and elicit a family history in patients with a ovarian mass or suspected OC.
E
Create free account

More topics in this section

  • Tumor markers

  • Diagnostic imaging

  • Imaging for staging

  • Genetic testing

Diagnostic procedures

Adnexal mass biopsy: as per ASCO 2021 guidelines, perform CT-guided biopsy or laparoscopy (with sufficient resources) instead of laparotomy to obtain histologic confirmation before any systemic therapy.
E
Create free account

More topics in this section

  • Histopathology

Medical management

Management of early-stage disease, surgical excision: as per ESGO 2017 guidelines, perform total hysterectomy and bilateral salpingo-oophorectomy as the standard of treatment in patients with stage I-II OC. Offer unilateral salpingo-oophorectomy in selected premenopausal patients desiring fertility preservation.
B
Show 2 more
Create free account

More topics in this section

  • Management of early-stage disease (intraoperative staging)

  • Management of early-stage disease (adjuvant chemotherapy)

  • Management of early-stage disease (PARPi regimens)

  • Management of advanced disease (neoadjuvant therapy)

  • Management of advanced disease (primary cytoreductive surgery)

  • Management of advanced disease (secondary cytoreductive surgery)

  • Management of advanced disease (chemotherapy)

  • Management of advanced disease (maintenance therapy)

  • Management of advanced disease (progressive disease)

  • Management of recurrent disease (general principles)

  • Management of recurrent disease (systemic therapy)

  • Management of recurrent disease (PARPi monotherapy)

Therapeutic procedures

Adnexal mass aspiration: as per RCOG 2016 guidelines, consider performing adnexal aspiration for symptom control in patients with advanced malignancy unfit for surgery or further intervention.
C
Create free account

Perioperative care

Postoperative care: as per ESGO 2017 guidelines, assess all patients postoperatively at a gynecological oncology multidisciplinary meeting.
E
Create free account

Surgical interventions

Technical considerations for surgery, general principles: as per ASCO 2021 guidelines, perform surgery by trained gynecologic oncologists or surgeons with oncology surgical expertise. Refer patients to the highest-resourced level oncology center with oncology surgical capacity.
E
Create free account

More topics in this section

  • Technical considerations for surgery (avoidance of intraoperative spillage)

  • Technical considerations for surgery (intraoperative frozen section examination)

Specific circumstances

Patients with non-epithelial OC, evaluation: as per ESMO 2018 guidelines, obtain pelvic ultrasound, abdominopelvic CT, CXR, and PET in the diagnostic work-up of selected patients with non-epithelial OC (germ cell tumor).
B
Show 9 more
Create free account

More topics in this section

  • Patients with non-epithelial OC (adjuvant chemotherapy)

  • Patients with non-epithelial OC (hormone therapy)

  • Patients with non-epithelial OC (radiotherapy)

  • Patients with non-epithelial OC (fertility preservation)

  • Patients with non-epithelial OC (surgical resection)

  • Patients with non-epithelial OC (follow-up)

Patient education

General counseling: as per ESMO 2016 guidelines, provide counseling in BRCA mutation carriers outlining options for screening for early detection, risk-reducing measures, and issues pertaining to fertility.
B
Create free account

More topics in this section

  • Genetic counseling (patients at risk)

  • Genetic counseling (patients with cancer)

Preventative measures

Lifestyle modifications: as per ESMO 2016 guidelines, advise exercising regularly, maintaining healthy body weight, limiting alcohol consumption, and avoiding hormone replacement therapy.
B
Create free account

More topics in this section

  • Hormone therapy

  • Aspirin

  • Risk-reducing salpingo-oophorectomy

  • Risk-reducing mastectomy

Follow-up and surveillance

Indications for referral: as per AAFP 2023 guidelines, refer patients with an adnexal mass and elevated CA-125 levels, high-risk ultrasound findings, or any other concern for ovarian malignancy to a gynecologic oncologist.
B
Create free account

More topics in this section

  • Management of treatment-related adverse events

  • Surveillance for recurrence

  • Surveillance for other malignancies (general principles)

  • Surveillance for other malignancies (breast cancer)

  • Surveillance for other malignancies (peritoneal cancer)

  • Surveillance for other malignancies (pancreatic cancer)

  • Surveillance for other malignancies (melanoma)